Non-melanoma skin cancers (NMSCs) are the most common malignancies after solid organ transplantation. Their incidence increases with time after transplantation. Calcineurin-inhibitors (CNIs) and azathioprine are known as skin neoplasia-initiating and -enhancing immunosuppressants. In contrast, increasing clinical experience suggests a relevant antiproliferative effect of mammalian target of rapamycin inhibitors, also named proliferation signal inhibitors (PSIs). We report the case of a cardiac allograft recipient with an impressive and consolidated reduction of recurrent NMSC, observed after conversion from CNI-therapy to a PSI-based protocol
Malignancies are a well-known complication of immunosuppressive therapy among renal transplant recip...
Background. Tumor recurrence represents the main limitation of liver transplantation in patients wit...
Abstract: Non-melanoma skin cancers represent a major cause of morbidity after organ transplantation...
Renal transplant recipients treated with calcineurin inhibitors (CNIs) are at a high risk of develop...
none15Although malignancy is a major threat to long-term survival of heart transplant (HT) recipient...
After kidney transplantation, withdrawal of calcineurin inhibitors (CNI) and conversion to sirolimus...
Sirolimus has antineoplastic effects and may reduce skin cancer rates in kidney transplant patients....
Calcineurin inhibitors (CNIs) have been associated in a dose-dependent fashion with an increased ris...
The risk of non-melanoma skin cancer (NMSC) is significantly increased in solid organ transplant rec...
Patients receiving immunosuppression to prevent organ transplant rejection are at a greatly increase...
Non-melanoma skin cancers represent a major cause of morbidity after organ transplantation. Squamou...
Malignancy after solid organ transplantation remains a major cause of posttransplant mortality. The ...
Transplantation is the treatment of choice for many different organ failures. Despite growing experi...
Introduction: The immunosuppressive efficiency obtained in the last decades in kidney transplantatio...
This was a systematic review of randomized controlled trials comparing delayed conversion of mammali...
Malignancies are a well-known complication of immunosuppressive therapy among renal transplant recip...
Background. Tumor recurrence represents the main limitation of liver transplantation in patients wit...
Abstract: Non-melanoma skin cancers represent a major cause of morbidity after organ transplantation...
Renal transplant recipients treated with calcineurin inhibitors (CNIs) are at a high risk of develop...
none15Although malignancy is a major threat to long-term survival of heart transplant (HT) recipient...
After kidney transplantation, withdrawal of calcineurin inhibitors (CNI) and conversion to sirolimus...
Sirolimus has antineoplastic effects and may reduce skin cancer rates in kidney transplant patients....
Calcineurin inhibitors (CNIs) have been associated in a dose-dependent fashion with an increased ris...
The risk of non-melanoma skin cancer (NMSC) is significantly increased in solid organ transplant rec...
Patients receiving immunosuppression to prevent organ transplant rejection are at a greatly increase...
Non-melanoma skin cancers represent a major cause of morbidity after organ transplantation. Squamou...
Malignancy after solid organ transplantation remains a major cause of posttransplant mortality. The ...
Transplantation is the treatment of choice for many different organ failures. Despite growing experi...
Introduction: The immunosuppressive efficiency obtained in the last decades in kidney transplantatio...
This was a systematic review of randomized controlled trials comparing delayed conversion of mammali...
Malignancies are a well-known complication of immunosuppressive therapy among renal transplant recip...
Background. Tumor recurrence represents the main limitation of liver transplantation in patients wit...
Abstract: Non-melanoma skin cancers represent a major cause of morbidity after organ transplantation...